1. Testosterone and its metabolites: Differential associations with cardiovascular and cerebrovascular events in men |
Page:109—114 |
2. Endogenous testosterone and mortality risk |
Page:115—119 |
3. Randomized controlled trials-mechanistic studies of testosterone and the cardiovascular system |
Page:120—130 |
4. Trials of testosterone replacement reporting cardiovascular adverse events |
Page:131—137 |
5. Testosterone treatment and cardiovascular events in prescription database studies |
Page:138—144 |
6. Would male hormonal contraceptives affect cardiovascular risk? |
Page:145—148 |
7. The expression of the new epididymal luminal protein of PDZ domain containing 1 is decreased in asthenozoospermia |
Page:154—159 |
8. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: Evidence from patients in Northwestern China |
Page:173—177 |
9. Phosphoglycerate mutase 1 knockdown inhibits prostate cancer cell growth, migration, and invasion |
Page:178—183 |
10. External validation and newly development of a nomogram to predict overall survival of abiraterone-treated, castration-resistant patients with metastatic prostate cancer |
Page:184—188 |
11. A retrospective review of single-institution outcomes with robotic-assisted microsurgical varicocelectomy |
Page:189—194 |
12. Association of subcutaneous testosterone pellet therapy with developing secondary polycythemia |
Page:195—199 |
13. Andrographolide sensitizes prostate cancer cells to TRAIL-induced apoptosis |
Page:200—204 |
14. Lipoxin A4 improves erectile dysfunction in rats with type i diabetes by inhibiting oxidative stress and corporal fibrosis |
Page:166—172 |
15. An in vitro prototype of a porcine biomimetic testis-like cell culture system: A novel tool for the study of reassembled Sertoli and Leydig cells |
Page:160—165 |
16. Diagnosis of a Chinese man with 45,X/46,X,i(Y)(q10)/47,X,i(Y) (q10) ×2 mosaic Turner syndrome. |
Page:205—207 |
17. Globozoospermic infertility associated with balanced DPY19L2 translocation/gene deletion at the chromosomal breakpoint. |
Page:210—211 |
18. Trials of testosterone replacement reporting cardiovascular adverse events. |
Page:131—137 |
19. Testosterone treatment and cardiovascular events in prescription database studies. |
Page:138—144 |
20. Andrographolide sensitizes prostate cancer cells to TRAIL-induced apoptosis. |
Page:200—204 |
21. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China. |
Page:173—177 |
22. Fertility achieved through in vitro fertilization in a male patient with 48,XXYY syndrome. |
Page:208—209 |
23. A retrospective review of single-institution outcomes with robotic-assisted microsurgical varicocelectomy. |
Page:189—194 |
24. External validation and newly development of a nomogram to predict overall survival of abiraterone-treated, castration-resistant patients with metastatic prostate cancer. |
Page:184—188 |
25. Lipoxin A4 improves erectile dysfunction in rats with type I diabetes by inhibiting oxidative stress and corporal fibrosis. |
Page:166—172 |
26. An in vitro prototype of a porcine biomimetic testis-like cell culture system: a novel tool for the study of reassembled Sertoli and Leydig cells. |
Page:160—165 |
27. Testosterone and its metabolites: differential associations with cardiovascular and cerebrovascular events in men. |
Page:109—114 |
28. Association of subcutaneous testosterone pellet therapy with developing secondary polycythemia. |
Page:195—199 |
29. Commentary on "Nondegloving technique for Peyronie's disease with penile prosthesis implantation and double dorsal-ventral patch graft". |
Page:212—212 |
30. Phosphoglycerate mutase 1 knockdown inhibits prostate cancer cell growth, migration, and invasion. |
Page:178—183 |
31. Would male hormonal contraceptives affect cardiovascular risk? |
Page:145—148 |
32. Endogenous testosterone and mortality risk. |
Page:115—119 |
33. The expression of the new epididymal luminal protein of PDZ domain containing 1 is decreased in asthenozoospermia. |
Page:154—159 |
34. Testosterone replacement therapy: Dilemmas and challenges in China and Asia. |
Page:149—151 |
35. Why is understanding the relationship of testosterone to cardiovascular risk so important? |
Page:107—108 |
36. Randomized controlled trials - mechanistic studies of testosterone and the cardiovascular system. |
Page:120—130 |
37. Conclusions about testosterone therapy and cardiovascular risk. |
Page:152—153 |